PR Newswire Clinical TrialsOriginal article
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
Phase 3positiveTrastuzumab BotidotinT-DM1Positive
AI Analysis
Summary
Sichuan Kelun-Biotech announced Phase III study results for trastuzumab botidotin versus T-DM1 in HER2-positive breast cancer, with findings published in the Journal of Clinical Oncology. The registrational trial data represents a significant milestone for the company's novel HER2-targeted antibody-drug conjugate.
Clinical Trial Data
Phase
Phase III
Outcome Details
Phase III registrational study results published in JCO
Importance:7/10
Sentiment:
0.70
HER2-positive breast cancerantibody-drug conjugatePhase III dataclinical trial resultsoncology
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 14, 2026 6:18 AM